These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26048605)

  • 41. Novel oral anticoagulants--key messages for the angiologist.
    Haas S; Spannagl M; Schellong SM
    Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
    Dias JD; Norem K; Doorneweerd DD; Thurer RL; Popovsky MA; Omert LA
    Arch Pathol Lab Med; 2015 May; 139(5):665-73. PubMed ID: 25927150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticoagulation therapy for atrial fibrillation.
    Hylek EM
    Semin Thromb Hemost; 2013 Mar; 39(2):147-52. PubMed ID: 23397554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
    Fontaine GV; Mathews KD; Woller SC; Stevens SM; Lloyd JF; Evans RS
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):665-72. PubMed ID: 24875781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.
    Di Minno MN; Russolillo A; Di Minno A; Camera M; Parolari A; Tremoli E
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):9-23. PubMed ID: 23448155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New anticoagulants for the prevention of stroke in atrial fibrillation.
    Höchtl T; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):47-53. PubMed ID: 21883447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
    Zikria J; Ansell J
    Discov Med; 2009 Dec; 8(43):196-203. PubMed ID: 20040270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antithrombotic management in atrial fibrillation].
    Fauchier L; Taillandier S; Clementy N
    Rev Prat; 2013 Feb; 63(2):199, 201-6. PubMed ID: 23513780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
    Stewart RA
    Curr Opin Cardiol; 2011 Jul; 26(4):294-9. PubMed ID: 21537165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study.
    Denas G; Fedeli U; Gennaro N; Ferroni E; Corti MC; Pengo V
    J Cardiovasc Med (Hagerstown); 2020 Jun; 21(6):415-419. PubMed ID: 32355064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
    Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
    Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Eur Heart J; 2013 Jul; 34(27):2094-106. PubMed ID: 23625209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
    Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room.
    Alturki A; Alamri A; Badawy M; Teitelbaum J
    World Neurosurg; 2016 Jun; 90():262-267. PubMed ID: 26960279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anticoagulation. Modern concepts].
    Perrey M; Erbel R
    Herz; 2012 Jun; 37(4):407-13; quiz 414-5. PubMed ID: 22592953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.